A new approach to multiple sclerosis treatment is moving from laboratory studies to human testing. Researchers at Johannes Gutenberg University Mainz have developed a skin patch designed to stimulate repair of damaged myelin, the protective coating around nerve fibers that multiple sclerosis (MS) attacks. The project has received EUR 1.1 million in funding to prepare the patch for clinical trials, marking a significant step toward testing whether this strategy can actually help people with MS recover lost nerve function.

Why Does MS Need a Repair-Focused Treatment?

Current MS medications work primarily by reducing inflammation and preventing new damage. However, they do not rebuild myelin that has already been destroyed. This repair process, called remyelination, remains an important unmet need in MS treatment. If researchers can successfully promote remyelination, it could help protect nerve fibers and support recovery in ways that today's drugs cannot.

The challenge is significant: while standard MRI scans may appear normal in early MS, subtle metabolic damage is occurring in the brain's white matter, the tissue rich in nerve fiber projections. A recent study of 51 people with early relapsing-remitting MS (RRMS), a form of the disease marked by flare-ups followed by periods of remission, found metabolic abnormalities in brain regions that looked normal on conventional imaging. This suggests that damage is happening at a microscopic level that current diagnostic tools may miss.

How Does the Mainz Patch Work?

The research team, led by Professor Claire Jacob, has studied myelin regeneration for more than 20 years. They identified histone deacetylase 2 (HDAC2), an enzyme involved in the cellular processes required for myelin repair. The researchers then investigated whether theophylline, a long-established medicine previously used at higher doses for asthma and respiratory conditions, could increase HDAC2 activity and promote myelin rebuilding.

In mouse studies, low-dose theophylline was associated with increased HDAC2 activity and improved myelin regeneration. Rather than using pills or injections, the team developed a transdermal patch that releases the drug through the skin. This delivery method offers several advantages:

• Stable Exposure: A patch maintains relatively consistent, low drug levels over several days, compared with the fluctuating levels from intermittent dosing.
• Safety Investigation: The patch provides a practical way to test whether the dose needed for remyelination can be delivered safely in humans.
• Practical Administration: A wearable patch is easier for patients to use than frequent injections or multiple daily pills.

It is important to note that these findings are preclinical. Results in mice cannot establish that the treatment will promote remyelination or improve neurological function in people with MS.

What Will the First Human Trial Involve?

The patch will first be transferred to a German manufacturer for optimization and production under Good Manufacturing Practice (GMP) standards, which are required before any medicinal product can be tested in human clinical trials. The planned phase I trial at Mainz University Medical Center will involve healthy volunteers, not people with MS.

The primary objectives of this initial trial will be to determine whether the delivery system produces the intended drug exposure and whether the patch is safe. This phase will not test whether the patch actually repairs damaged myelin or benefits people with MS. Testing healthy volunteers is a standard first step to establish safety and confirm that the drug reaches the body at the intended levels. Only later controlled studies in people with MS can determine whether the approach promotes remyelination, improves function, and has an acceptable safety profile.

What Do Early Brain Imaging Studies Reveal About MS Damage?

While the Mainz patch moves toward human testing, complementary research is revealing just how subtle and widespread MS damage can be. European scientists used a specialized imaging technique called proton magnetic resonance spectroscopy (1H-MRS) to examine the brains of 51 people with early RRMS and 44 healthy controls. All participants were approximately 40 years old, and 81% were women.

The researchers examined six white matter regions throughout the brain that appeared normal on standard MRI scans. They found significant metabolic differences between MS patients and healthy controls:

• Nerve Fiber Health Marker: In four of six brain regions, a measure called the N-acetylaspartate-to-creatine ratio (NAA/Cr), which indicates nerve cell health, was lower in MS patients, suggesting reduced nerve cell integrity.
• Myelin Breakdown Signal: The choline-to-creatine ratio was elevated in four of six regions among people with MS, consistent with increased breakdown of cell membranes and myelin loss.
• Brain Support Cell Activity: Changes in the myo-inositol-to-creatine ratio, which reflects activity of nerve support cells called glia, varied by location, demonstrating that metabolic abnormalities were not uniform throughout the brain.

The researchers then examined whether these metabolic changes were associated with cognitive function in the MS patients. They found that metabolic measures in several brain regions, particularly the frontal white matter, were significantly associated with scores on the Multiple Sclerosis Functional Composite, a broader measure combining walking ability, arm and hand function, and cognitive processing. However, the links between metabolic markers and purely cognitive measures were weak and did not remain significant after adjusting for other variables.

The study had important limitations: it was relatively small, and patients were assessed at only a single point in time. This prevents determining whether metabolic abnormalities occur before or after cognitive changes. Larger studies following patients over time will be needed before these measures can be considered potential disease biomarkers.

What This Means for MS Patients and Research

The Mainz patch project represents a shift in MS treatment strategy. Rather than only controlling inflammation, researchers are now developing therapies specifically designed to repair existing myelin injury. The significance lies in addressing a therapeutic goal that current approved treatments cannot achieve.

The imaging research underscores why this repair-focused approach matters: MS causes metabolic damage at the microscopic level that standard diagnostic tools may miss. By the time cognitive or physical symptoms become apparent, significant cellular injury has already occurred. A treatment that can rebuild myelin could potentially slow or reverse this damage if delivered early enough.

The path from mouse studies to human benefit is long and uncertain. The upcoming phase I trial will answer basic questions about safety and drug delivery. Only if those results are promising will researchers move forward with trials in people with MS to determine whether the patch actually promotes remyelination and improves neurological function. Still, the combination of two decades of focused research, substantial funding support, and a clear therapeutic target suggests that this approach warrants careful attention as it advances through the clinical trial process.